Could a failed ulcer drug help regrow insulin cells in type 1 diabetes?

NCT ID NCT06474598

Recruiting now Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a drug called MTX228 (Tolimidone) in 24 adults with type 1 diabetes who still produce some insulin. The goal is to see if the drug can help regrow the beta cells that make insulin, which could lower the amount of insulin they need to inject and improve blood sugar control. Researchers will compare different doses to find the most effective one for a future larger study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MTX228 (Tolimidone)
What this could lead to: If successful, this could point toward a treatment that helps people with type 1 diabetes produce some of their own insulin again, reducing their need for injected insulin.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply widely. The drug previously failed for other conditions, and its effect on beta-cell regrowth is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

University of Alberta
RECRUITING

Edmonton, Alberta, T6G 2R3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.